Cardiotoxic effects of BRAF/MEK inhibition: An observational study
CTRCD is frequent among patients treated with BRAF/MEK inhibitors. Traditional cardiovascular risk factors were not predictive, although coronary artery disease emerged as a strong risk marker. These findings highlight the need for dynamic surveillance strategies.
Institutions
- German Cancer Research Center (DE)
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
Publication Details
- Journal
- European Journal of Cancer
- Published
- 2025-12-12
- DOI
- https://doi.org/10.1016/j.ejca.2025.116182
- Citations
- 1
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.81